In this issue:
Survival outcomes after A+AVD vs ABVD in advanced Hodgkin lymphoma
Continuous vs intermittent zandelisib ± rituximab in patients with R/R B-cell malignancy
Zanubrutinib vs bendamustine-rituximab in untreated CLL or SLL
Mosunetuzumab in patients with R/R follicular lymphoma
Lisocabtagene maraleucel in patients with R/R large B-cell lymphoma not intended for HSCT
DDGP vs SMILE regimen for newly diagnosed advanced ENKL
Pembrolizumab for the treatment of R/R classical Hodgkin lymphoma before ASCT
ZUMA-5 vs SCHOLAR-5 trial in patients with R/R follicular lymphoma
Real-world study of CAR T-cell therapies for large B-cell lymphoma
Impact of MRD status in patients with AML undergoing alloSCT in first vs second remission
Please login below to download this issue (PDF)